Venkat Krishnamurthy
Company: Korro Bio
Job title: Senior Vice President & Head Of Platform & Ribonucleic Acid Editing
Seminars:
Roundtable Discussion: Discussing Strategies for Improved Longevity of Editing Therapeutics to Achieve More Durable Effects 11:00 am
How can the delivery platform used enhance the durability of the RNA editing machinery? Is it possible to incorporate self-replicating RNA for continued editing to increase longevity? What strategies is the community currently trying to improve durability? Is it possible to incorporate the RNA editing system into the genome?Read more
day: Conference Day Two
Chair’s Opening Remarks 8:50 am
day: Conference Day One
Chair’s Closing Remarks & End of Conference Day One 5:00 pm
day: Conference Day One
Edit the Message: Rewrite the Future 1:30 pm
At Korro Bio, we are developing our proprietary OPERA platform (Oligonucleotide Promoted Editing of RNA), which utilizes synthetic oligonucleotides that recruit adenosine deaminases acting on RNA (ADARs) to repair disease-causing mutations at the RNA level In addition to repairing standard G-to-A mutations, our platform enables the modulation of protein function by changing the amino acid…Read more
day: Conference Day Two